FOLFOXIRI <i>vs</i> FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study.

World J Gastrointest Oncol · 2020 · PMC7081111 · PMID 32206183

Europe PMC DOI

hedged sentence

0.0790

closest p · 1.6× alpha

0.0790

boldest claim

The sentences

did not reach statistical significanceP = 0.079so close (0.05 < p ≤ 0.1)

Grade 3 or 4 toxicities occurred in 19.5% of patients in the FOLFIRINOX group as compared with 28.7% in the FOLFOXIRI group, but this difference did not reach statistical significance ( P = 0.079).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.